Viking Therapeutics, Inc.
Viking Therapeutics, Inc. logo
VKTX

Viking Therapeutics, Inc. (VKTX)

$4.040.75%

Live
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$4.005
Day's Range
$4.17
$2.02
52-Week Range
$5.65
1 month return3.61%
3 month return21.15%
1 year return24.62%
5 year return42.2%

Company Information

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1 first-in-human clinical trial. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.
OrganizationViking Therapeutics, Inc.
Employees16
CEODr. Brian Lian Ph.D.
IndustryHealth Technology

Analyst Recommendation

based on 11 analysts ratings

Buy
100%
Buy
0%
Hold
0%
Sell

Based on 11 Wall street analysts offering stock ratings for Viking Therapeutics, Inc.(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 331.68%

Current

$4.04

Target

$17.44

Recommendation Trend

Based on 11 analyst

Current1M Ago3M Ago
Buy
11
15
15
Hold
0
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Highlights

Market Capitalization
311.3M
Book Value
$1.97
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.73
PEG Ratio
-0.03
Wall Street Target Price
17.44

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
2.07
Enterprise Value
160.3M
Enterprise Value/Revenue
0.0
Enterprise Value/Ebitda
-2.57

Technicals

Beta
1.47
50 Day MA
3.58
200 Day MA
3.14

Institutional Holdings

Vanguard Group Inc

4.34%

Balyasny Asset Management LLC

3.45%

Park West Asset Management LLC

3.22%

LAURION CAPITAL MANAGEMENT LP

1.73%

Millennium Management LLC

1.71%

Two Sigma Advisers, LLC

1.46%

Discover more

Frequently Asked Questions

What is Viking Therapeutics, Inc. share price today?

Can Indians buy Viking Therapeutics, Inc. shares?

How can I buy Viking Therapeutics, Inc. shares from India?

Can Fractional shares of Viking Therapeutics, Inc. be purchased?

What are the documents required to start investing in Viking Therapeutics, Inc. stocks?

What are today’s High and Low prices of Viking Therapeutics, Inc.?

What are today’s traded volumes of Viking Therapeutics, Inc.?

What is today’s market capitalisation of Viking Therapeutics, Inc.?

What is the 52 Week High and Low Range of Viking Therapeutics, Inc.?

How much percentage Viking Therapeutics, Inc. is down from its 52 Week High?

How much percentage Viking Therapeutics, Inc. is up from its 52 Week low?

What are the historical returns of Viking Therapeutics, Inc.?

Who is the Chief Executive Officer (CEO) of Viking Therapeutics, Inc.?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*